Skip to main content

Table 4 Associations of percent density with ER-positive and ER-negative breast cancer, by BMI and menopausal status for 1823 cases and 4720 controls

From: Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype

 

Normal/underweight

BMI < 25 kg/m2

Overweight/obese

BMI ≥ 25 kg/m2

 

Cases

Controls

Percent density

OR per S.D. (95% CI)a

P het b

Cases

Controls

Percent density

OR per S.D. (95% CI)a

P het b

Premenopausalc

   

0.27

   

0.01

 ER-positive cancer

325

979

1.90 (1.57–2.29)

 

180

528

1.33 (1.11–1.61)

 

 ER-negative cancer

58

979

1.51 (1.04–2.21)

 

47

528

2.17 (1.50–3.16)

 

Postmenopausal HT userd

   

0.22

   

0.89

 ER-positive cancer

240

678

1.71 (1.42–2.05)

 

171

446

1.60 (1.30–1.96)

 

 ER-negative cancer

41

678

1.34 (0.92–1.94)

 

27

446

1.66 (1.06–2.60)

 

Postmenopausal HT non-usere

   

0.25

   

0.66

 ER-positive cancer

228

1029

1.51 (1.27–1.80)

 

394

1060

1.50 (1.31–1.71)

 

 ER-negative cancer

51

1029

1.23 (0.89–1.70)

 

61

1060

1.40 (1.04–1.87)

 
  1. Abbreviations: BMI body mass index, CI confidence interval, ER estrogen receptor, HT hormone therapy, OR odds ratio, S.D. standard deviation
  2. aOdds ratios estimated from polytomous multivariable logistic regression models adjusted for age, study. Standard deviation of square root-transformed percent density = 2.0
  3. bP value of heterogeneity of association between percent density and ER subtypes within BMI groups
  4. cPint = 0.008 for BMI-percent density interaction within premenopausal women
  5. dPint = 0.58 for BMI-percent density interaction within postmenopausal HT users
  6. ePint = 0.89 for BMI-percent density interaction within postmenopausal HT non-users
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us